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Background: The Hedgehog (Hh) signaling pathway is
critical for embryonic development and its deregulation
is implicated in a number of tumor types. The role of the
Hh signaling pathway, however, in the initiation and
growth of non-small cell lung cancer is largely unknown.
Here, we investigate the role of the Hh pathway tran-
scription factor, GLI1, in lung squamous cell carcinoma
(SCC) and as a potential therapeutic target for treatment
of lung SCC.
Methods: GLI1 expression in human SCC cell lines was
evaluated by quantitative PCR and Western Blot. siRNA
and shRNA of GLI1 in these cell lines were utilized in
vitro and in vivo to test the requirement of GLI1 in tumor
growth. Small molecule modulators of GLI1 were tested
for their therapeutic potential.
Results: GLI1 mRNA expression was signiﬁcantly
elevated in lung SCC compared to normal lung and
lung adenocarcinoma patient specimens in several
human genomic databases. Importantly, over-
expression of GLI1 was correlated with poor overall
survival in lung cancer patients. siRNA-mediated
knock down of GLI1 in SCC cell lines decreased the
expression of GLI1 target genes and caused a signiﬁ-
cant reduction in colony formation. Stable knock down
of GLI1 in SCC cell lines caused a signiﬁcant reduction
in growth of xenograft tumors indicating the critical
role of GLI1 in lung SCC progression. Inhibition or
activation of SMO, an upstream component of Hh
pathway, did not alter GLI1 expression level in lung
SCC cell lines. However, inhibition of PI3K/AKT and
MAPK signaling pathways down-regulated GLI1
expression, suggesting that GLI1 expression is depen-
dent on PI3K/AKT and MAPK pathway activity rather
than Hh ligand. Small molecule inhibition of PI3K/
mTOR pathway or GLI1 signiﬁcantly reduced GLI1
expression, proliferation, and clonogenicity in SCC cell
lines. Combinatorial inhibition of PI3K and GLI1 by
BKM120 and arsenic trioxide (ATO), respectively,
signiﬁcantly abrogated the in vivo growth SCC tumors
in mice and correlated with decreased tumor GLI1
expression.Conclusion: Our ﬁndings demonstrate that GLI1 is
essential for lung SCC tumor progression. Furthermore,
GLI1 expression in SCC is independent of Hh pathway
ligand action and dependent on MAPK and PI3K pathway
activity. Direct inhibition of GLI1 by repurposing ATO in
combination with a PI3K inhibitor may represent a novel
therapeutic strategy for lung SCC.Validation of L-Myc as a viable
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Background and Hypothesis: The paucity of molecu-
lar targets for small cell lung cancer (SCLC) chemo-
prevention and therapy is largely due to the poor
understanding of SCLC progression beyond the role of
RB and P53 mutations crucial for tumor initiation.
Ampliﬁcation of the Myc family of oncogenes is one of
the most frequent alterations in human SCLC ge-
nomes. However, the concept of inhibiting these fac-
tors to intervene in SCLC progression, despite its clear
value as a targeted therapy, has not been formally
tested in the autochthonous model. We tested the
hypothesis that L-Myc is a key determinant of SCLC
and its pathway as a viable target for therapeutics
and chemoprevention.
Methods and Results: Using comparative gene
expression analysis of pre-cancerous cells (preSC) and
tumor cells, both derived from the genetically engi-
neered mouse model (GEMM), we identiﬁed a gene set
speciﬁc to SCLC tumorigenic progression and found
that L-Myc is the most up-regulated gene in the mouse
model. Retroviral overexpression of L-Myc, mimicking
the gene ampliﬁcation, was sufﬁcient to cause the
tumorigenic progression of the L-Myc-expressing preSC
in culture or allograft experiment, while CRISPR-medi-
ated knockout of L-Myc blocked the long-term growth of
SCLC cells in culture. Comparison of L-Myc-preSC with
control (non-transformed) preSC revealed a speciﬁc
gene signature, and the pathway analysis of the signature
indicated signiﬁcant activation of several molecular
pathways, including epithelium-to-mesenchyme transi-
tion, downstream of L-Myc during tumor progression.
More signiﬁcantly, conditional deletion of L-Myc in
the GEMM dramatically reduced tumor burden in a
